Alexandria® — the world’s largest body of medical evidence for clinical decision support and LLM training.

Read the release
Learn more
Logo
  • Solutions
        • Health Systems
          • Pharmacy
          • Research Informatics
          • Value Based Care / Quality
          • GME
        • Life Sciences
          • Brand Planning
          • Precision Medicine AI/ML
          • HEOR, Medical Affairs & RWE
          • Research & Development
          • Commercial Analytics
  • Technology
        • Content
          • Alexandria®
        • Automation Solutions
          • Atropos Evidence™ Agent
          • ChatRWD®
          • Green Button®
          • Forge®
        • Data
          • GENEVA OS®
          • Atropos Evidence™ Network
          • Data Quality Scoring
  • About
    • About Us
    • Careers
  • Resources
    • Resource Center
    • Publications
    • Customer Stories
    • News & Media
    • Press Releases
    • Blog
  • Contact Us
  • Login
State of digital health investment, part 4: Atropos Health

State of digital health investment, part 4: Atropos Health

by Julia Rudo | Aug 15, 2024 | News and Media

“The perspective on seeking investment varies company by company. Still, a common theme exists that it is necessary to ensure knowledge of the market and the actual value of one’s technology and that the company’s cash runway does not disappear...
Real-World Evidence Assessment of the  Risk of Nonarteritic Anterior Ischemic  Optic Neuropathy in Patients Prescribed  Semaglutide

Real-World Evidence Assessment of the Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide

by Julia Rudo | Aug 1, 2024 | Publications

An article titled, “Real-World Evidence Assessment of the Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide,” was published in Journal of Diabetes Science and Technology by authors David C. Klonoff, MD, FACP, FRCP...
GLP-1 RA and Risk of Malignancy in Patients with Type 2 Diabetes

GLP-1 RA and Risk of Malignancy in Patients with Type 2 Diabetes

by Julia Rudo | Jun 14, 2024 | Publications

An abstract titled, “GLP-1 RA and Risk of Malignancy in Patients with Type 2 Diabetes,” was published in Diabetes, a publication from the American Diabetes Association, and subsequently presented by authors Faidat A. Ishola, C. William Pike, and Sun H. Kim. Dr. Pike...
GLP-1 Agonists Can Prevent Liver Disease Progression in Patients with Metabolic and Alcohol-Associated Liver Disease (METALD)

GLP-1 Agonists Can Prevent Liver Disease Progression in Patients with Metabolic and Alcohol-Associated Liver Disease (METALD)

by Julia Rudo | May 20, 2024 | Publications

An abstract titled, “GLP-1 Agonists Can Prevent Liver Disease Progression in Patients with Metabolic and Alcohol-Associated Liver Disease (MetALD),” was published in Digestive Disease Week and subsequently presented by authors Amir Gougol, C. William Pike, Niloufar...
Generative Terminology Mapping of Text Strings to RxNorm

Generative Terminology Mapping of Text Strings to RxNorm

by Julia Rudo | May 1, 2024 | Presentations, Publications

A presentation titled, “Generative Terminology Mapping of Source Medication Terms to RxNorm: Using LLMs as Clinical Expert Reviewer,” was given at the 2024 NLP Summit to the American Medical Informatics Association by authors Philip Ballentine, MSc and C....
« Older Entries
Next Entries »
DiviWP Logo
  • Follow
  • Follow

Solutions

Health Systems

Pharmacy

Research Informatics

Value Based Care / Quality

GME

Life Sciences

Brand Planning

Precision Medicine AI/ML

HEOR, Medical Affairs & RWE

Research & Development

Commercial Analytics

Technology

Content

Alexandria®

Automation Solutions

Atropos Evidence™ Agent

ChatRWD®

Green Button®

Forge®

Data

GENEVA OS®

Atropos Evidence™ Network

Data Quality Scoring

About

  • About Us
  • Careers

Resources

  • Resources Center
  • Publications
  • Customer Stories
  • News & Media
  • Press Releases
  • Blog

Copyright © 2026 Atropos Health. All Rights Reserved | Privacy Policy | Ethics Report | Terms of Service

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}